Werner Liliana
John A. Moran Eye Center, University of Utah, Salt Lake City, Utah 84132, USA.
Curr Opin Ophthalmol. 2008 Jan;19(1):41-9. doi: 10.1097/ICU.0b013e3282f20132.
To provide an update on currently available materials used in the manufacture of intraocular lenses, as well as new materials under development, especially with regard to their uveal and capsular biocompatibility.
The biocompatibility of intraocular lens materials should be assessed in terms of uveal biocompatibility, related to the inflammatory foreign-body reaction of the eye against the implant, as well as in terms of capsular biocompatibility, determined by the relationship of the intraocular lens with remaining lens epithelial cells within the capsular bag. This situation may result in different entities, e.g. anterior capsule opacification, interlenticular opacification (between piggyback intraocular lenses), posterior capsule opacification and lens epithelial cell ongrowth. Reports on intraocular lens opacification suggest that the potential to calcify should also be taken into consideration when evaluating the long-term biocompatibility of a new material.
Intraocular lenses are being progressively implanted in much earlier stages of life (refractive lens exchange, pediatric implantation) and are expected to remain in the intraocular environment for many decades. Materials used in intraocular lens manufacture should, therefore, insure long-term uveal and capsular biocompatibility, as well as ultimate transparency after implantation.
介绍目前用于制造人工晶状体的材料以及正在研发的新材料的最新情况,尤其关注它们与葡萄膜和晶状体囊的生物相容性。
人工晶状体材料的生物相容性应从葡萄膜生物相容性(与眼睛对植入物的炎症性异物反应相关)和晶状体囊生物相容性(由人工晶状体与晶状体囊袋内残留晶状体上皮细胞的关系决定)两方面进行评估。这种情况可能导致不同的问题,如前囊膜混浊、双焦人工晶状体间混浊、后囊膜混浊和晶状体上皮细胞增生。关于人工晶状体混浊的报告表明,在评估新材料的长期生物相容性时,钙化的可能性也应予以考虑。
人工晶状体正越来越多地被植入生命的早期阶段(屈光性晶状体置换、儿童植入),并预计在眼内环境中留存数十年。因此,用于制造人工晶状体的材料应确保长期的葡萄膜和晶状体囊生物相容性以及植入后的最终透明度。